Expert Interview
What Should We Expect from CytRx Phase 3 Data for Aldoxorubicin in Soft Tissue Sarcoma Coming July 2016?
Ticker(s): CYTRA physician with broad experience treating soft tissue sarcoma and a familiarity with aldoxorubicin. This could potentially be a medical oncologist, thoracic surgeon, orthopedic surgeon, a radiation oncologist, or something similar.
What is your background treating soft tissue sarcomas?
Added By: kcmckeeWhat are your thoughts on the aldoxorubicin data presented thus far (phase 1 and 2)? What would you be looking for in Phase 3? What do you expect to see?
Added By: kcmckeeWith a variety of types of treatment available for sarcomas, what do you think are the most promising now and what will be going forward?
Added By: kcmckeeWhat do currently prescribe or use to treat sarcomas? Why? Would you ever consider aldoxorubicin?
Added By: kcmckeeDo you think aldoxorubicin could have applications beyond soft tissue sarcomas in the future?
Added By: kcmckeeAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- CytRx Expects Phase 3 Data for Aldoxorubicin in Soft Tissue Sarcoma July 2016 CYTR Occurred On: Jul 11, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
